December - 2020

MECFA Blog

MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Swiss biotech Polyphor’s first-in-human phase I study...

Antifungal drug improves key cystic fibrosis biomarkers in clinical study

A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in the noses of patients with...

Potential Antibiotic Appears to Effectively Treat M. abscessus Infections

A newly developed antibiotic, called T405, appears to effectively kill Mycobacteroides abscessus, a difficult-to-treat bacteria that can...

Production Increases for Pyocin S5, Potential Antibiotic for Treating Lung Disease

Project GAIA, establishing a large-scale manufacturing process for Pyocin S5, an investigational antibiotic for the treatment of lung...

Antifungal drug improves key cystic fibrosis biomarkers in clinical study

CHICAGO, Dec. 18 (Xinhua) -- A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in...

Beyond Air Launches Pivotal Trial of LungFit Go Inhaled NO for NTM Lung Infections

Beyond Air has launched a pilot clinical trial evaluating its investigational therapy LungFit GO — inhaled nitric oxide that can be...

Defects in Mitochondria May Sustain Burkholderia Cenocepacia Infections in CF

Specific immune cells called macrophages in cystic fibrosis (CF) are unable to kill the bacteria Burkholderia cenocepacia due to...

CF Children With COVID-19 Usually Do Not Develop Serious Disease, Study Finds

Children with cystic fibrosis (CF) who become infected with SARS-CoV-2 — the virus that causes COVID-19 — usually have a mild disease...

BiomX Testing Potential Therapy for CF Lung Infections

BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is using to test...

Phase 3 ASPEN Trial Testing Brensocatib Now Recruiting; First Patient Dosed

The first participant has been dosed in ASPEN, a Phase 3 trial — now recruiting patients — that is evaluating the investigational...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p